May 16 2013 – Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients with IPF at the ATS 2013 Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--May 16, 2013--

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that data from a clinical study of PRM-151 in patients with idiopathic pulmonary fibrosis (IPF) will be presented in an oral presentation at the 2013 American Thoracic Society (ATS) International Conference being held from May 17-22, 2013, in Philadelphia, Penn. The clinical data to be presented are from a randomized, double-blind, placebo controlled Phase 1b multiple ascending dose study which examined safety and tolerability, as well as exploratory efficacy endpoints.

Read the entire article at:

http://online.wsj.com/article/PR-CO-20130516-909919.html?mod=googlenews_wsj

For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com

This entry was posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized and tagged , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>